1. Failure to respond to an ANDA complete response letter within the regulatory timeframe Publication: Silver Spring, MD : Center for Drug Evaluation and Research, July 2022 Subject(s): Correspondence as TopicDrug ApprovalGovernment RegulationUnited StatesUnited States. Food and Drug Administration
